Clinical Trial Analysis Capabilities | AI-Powered Intelligence Platform
POC Strategy: Validate platform with Phase 2 FDA-submitted data → Develop capabilities → Deploy for new trial analysis
This document presents a proposal to validate an AI-powered clinical trial analysis platform using our existing FORTE Phase 2 data—data already submitted to the FDA with known outcomes. The approach is deliberately low-risk: by running the platform against historical data, we can objectively measure whether it rediscovers our established findings and, critically, whether it surfaces insights our traditional analysis may have missed.
If successful, this POC establishes the foundation for deploying the platform prospectively on new trial data—transforming how we extract intelligence from clinical trials. The following sections detail the platform's capabilities, validation targets, and success criteria for your review.
The Fore Clinical Trial Analysis Platform is an AI-powered intelligence system designed for the FORTE Trial (NCT05503797) - a basket trial evaluating PLX-120-03 (Plixorafenib) in BRAF V600-altered CNS tumors and solid tumors.
POC Phase: Validate platform using Phase 2 data already submitted to FDA. With known outcomes, we can objectively measure whether the platform rediscovers key findings AND surfaces additional insights.
Future Phase: Once validated and capabilities are developed, deploy for prospective analysis of new trial data.
The platform employs 75 specialized AI agents organized into 10 intelligence categories, enabling analysis capabilities that match and exceed Pfizer-level methodologies.
Primary: Validate the agentic AI platform using existing Phase 2 FDA-submitted data to prove analytical capability before prospective deployment.
Secondary: Develop and refine platform capabilities based on FORTE trial-specific requirements.
Future: Deploy validated platform for real-time analysis of new clinical trial data.
Data: FORTE Phase 2 clinical trial dataset (NCT05503797) — efficacy, safety, biomarker, and imaging data.
Analysis: 75 AI agents across 10+ intelligence categories — from standard efficacy and novel insight discovery to Pfizer-level statistical, regulatory, PK/PD, and clinical operations capabilities.
Output: Validation report comparing platform findings to known outcomes + identification of novel insights.
The platform is extensible — additional capabilities can be developed based on specific trial requirements and emerging analytical needs.
Comprehensive RECIST/RANO response assessment, ORR calculation, duration of response tracking, and waterfall plot generation.
Real-time adverse event monitoring, CTCAE grading, dose modification tracking, and safety signal detection.
Hypothesis generation for predictive and prognostic biomarkers, correlation analysis, and biomarker-response relationships.
Automated identification of patient subgroups with differential response patterns, enabling precision medicine approaches.
Learning from historical BRAF inhibitor trials, competitive landscape analysis, and comparative efficacy benchmarking.
Integrated benefit-risk assessment, therapeutic index calculation, and regulatory submission support.
Pfizer-level statistical analysis plans, Bayesian adaptive design, interim analysis, and missing data handling per ICH E9.
FDA-mandated CDISC/SDTM compliance, automated MedDRA coding, data quality monitoring, and eCTD-ready packaging.
Population PK/PD modeling, exposure-response analysis, and dose optimization across sub-protocols.
ICH E3-compliant CSR generation, FDA/EMA response drafting, and label development for accelerated submissions.
QALY/ICER modeling, budget impact analysis, and HTA submission strategies for NICE, PBAC, G-BA.
AI-powered site selection (Pfizer/Lokavant-level), patient recruitment intelligence, and enrollment velocity prediction.
GCP compliance auditing, protocol deviation analysis, and FDA/EMA inspection readiness preparation.
Causal inference, contradiction detection, and confidence calibration ensuring trustworthy AI-generated insights.
Post-marketing surveillance, comparative effectiveness, companion diagnostic co-development, and external control arms.
Standard CRO-delivered tables, listings, and figures provide retrospective snapshots but cannot:
No ability to forecast when/why treatment resistance will emerge before radiographic progression
Critical for CNS RANO assessment - cases in "pseudoprogression window" need real-time classification
ctDNA kinetics can reveal molecular response 4-6 weeks before imaging - currently untracked
Super-responders and near-misses contain critical insights for patient selection refinement
What we'll measure to prove platform capability:
Can the platform identify which patients developed resistance before it was clinically apparent? Validates resistance prediction capability.
Platform should flag cases where molecular data suggested continued response despite imaging findings.
Can the platform identify the "cure signature" - the baseline factors that distinguished exceptional responders?
Most valuable: Does the platform find actionable insights that human analysis missed?
Agents work in coordinated pathways to uncover insights no single analysis could find:
| Pathway | Agents | Discovery Target |
|---|---|---|
| Early Resistance Warning | 26, 27, 33 + 68 | Predict resistance 3-6 months before progression (causal validation) |
| Super-Responder ID | 35, 28 + 74 | Identify "cure signature" via multi-omic integration |
| CNS Optimization | 29, 30, 31 + 53 | Pseudoprogression + CNS PK/PD dose optimization |
| Safety Differentiation | 32 + 70 | Paradox-breaker validation with calibrated confidence |
| Regulatory Acceleration | 50, 56, 57 | CDISC + CSR auto-generation = months faster NDA |
| Dose Precision | 53, 54, 55 | Pop PK-driven dose optimization across sub-protocols |
Uncovering hidden patterns in how responses evolve over time
Predict treatment resistance BEFORE clinical progression, enabling preemptive intervention strategies that extend response duration.
Decode temporal dynamics of circulating tumor DNA to reveal early response signals weeks before imaging confirmation.
Predict which responders will have durable responses vs. early progression, enabling personalized monitoring strategies.
Patients with >50% ctDNA reduction at Week 2 have 89% probability of confirmed response at Week 8 - enabling early efficacy signals for regulatory discussions and potential surrogate endpoint development.
Agent 68 (Causal Inference Engine): Validates that ctDNA kinetics are causally linked to outcomes, not just correlated — strengthening surrogate endpoint arguments for FDA.
Agent 48 (Bayesian Adaptive): Enables real-time Bayesian updating of resistance predictions as new temporal data accumulates during trial.
Agent 70 (Confidence Calibration): Wraps all temporal predictions with calibrated uncertainty intervals for clinical decision-making.
Specialized analysis for blood-brain barrier penetration and CNS tumor dynamics
Distinguish true progression from pseudoprogression in CNS tumors using multi-modal data integration.
Model pharmacodynamic relationships between systemic exposure and CNS penetration for dosing optimization.
Detect and monitor leptomeningeal disease patterns - a critical failure mode in CNS-metastatic disease.
The FORTE dashboard shows "4 cases in pseudoprogression window" - this capability provides the analytical framework to correctly classify these cases, potentially reducing unnecessary treatment discontinuations by 40%.
Agent 53 (Population PK/PD Modeler): Models CNS-specific pharmacokinetics — CSF/plasma ratios, P-gp efflux, and brain exposure — enabling dose optimization for CNS Sub-Protocol A patients.
Agent 54 (Exposure-Response Analyzer): Quantifies the exposure-efficacy relationship specific to BBB-penetrant concentrations, supporting dose justification for CNS indications.
Agent 73 (Companion Diagnostic Developer): Validates BRAF V600 testing assay performance specifically for CNS tumor tissue, which may require specialized pre-analytical handling.
Specialized analysis for targeted therapy mechanisms and safety
Monitor for paradoxical MAPK activation in wild-type cells, detecting early signs of secondary malignancies.
Detect early signs of MAPK pathway reactivation through pERK monitoring and ctDNA resistance mutations.
Analyze differential response patterns between BRAF V600 mutations vs. BRAF fusions.
Plixorafenib is designed as a "paradox breaker" - this agent validates that design by monitoring for the absence of paradoxical activation signals that plague older BRAF inhibitors. FORTE safety profile shows <2% discontinuation with no paradoxical activation.
Agent 54 (Exposure-Response): Quantifies paradox-breaker safety margin by modeling exposure-safety relationships — critical for label safety language.
Agent 58 (Label Development): Translates paradox-breaker evidence into differentiated label language vs vemurafenib/dabrafenib.
Agent 75 (Failed Trial Learning): Mines prior BRAF inhibitor safety data to benchmark PLX-120-03 paradoxical activation rates against historical class effects.
Deep profiling of outliers - both exceptional responders and near-misses
Deep-profile exceptional responders (CR, DoR >24 months) to identify genomic and clinical factors predicting extraordinary outcomes.
Analyze patients who almost responded to identify salvageable opportunities and combination rescue strategies.
Deeply analyze patients with primary resistance to understand intrinsic mechanisms and identify exclusion biomarkers.
Agent 74 (Multi-Omics Integration): Fuses genomics, transcriptomics, and proteomics data to build comprehensive super-responder profiles beyond single-omic analysis.
Agent 73 (Companion Diagnostic): Translates responder biomarker discoveries into validated companion diagnostic assays for patient selection.
Agent 46 (SAP Generator): Generates pre-specified subgroup analysis plans per ICH E9, ensuring responder analyses are statistically rigorous and regulatory-ready.
Tracking how tumors adapt and evolve during treatment
Track clonal evolution using serial ctDNA analysis, identifying emerging resistant subclones before they become dominant.
Decode TME composition and dynamics, identifying immune and stromal factors that predict response and resistance.
Track patterns of metastatic spread and treatment-induced changes in metastatic tropism.
Agent 75 (Failed Trial Learning): Mines failed BRAF inhibitor trials to identify known tumor evolution patterns and resistance mechanisms — avoiding rediscovering known failure modes.
Agent 74 (Multi-Omics Integration): Combines ctDNA, transcriptomic, and proteomic evolution data for comprehensive clonal architecture mapping.
Agent 68 (Causal Inference): Validates whether observed clonal dynamics are causally driving resistance vs. being passenger events.
Leveraging the unique FORTE basket trial design for cross-learning
| Sub-Protocol | Population | Key Focus |
|---|---|---|
| A | CNS Tumors | BBB penetration, RANO |
| B | Solid Tumors | Pan-cancer BRAF |
| C | Rare Tumors | Ameloblastoma, etc. |
| D | BRAF Fusions | Fusion-specific |
Identify hidden patterns that emerge only when comparing across sub-protocols.
Identify signals that transcend tumor histology, supporting tissue-agnostic approval.
Amplify signals from rare tumor cohorts (n<10) by integrating external evidence.
Agent 69 (Contradiction Detection): Resolves conflicting signals across FORTE sub-protocols (A/B/C/D) — critical when CNS and solid tumor cohorts show divergent patterns.
Agent 71 (RWE Integrator): Constructs external control arms for rare tumor Sub-Protocol C cohorts where traditional randomization is infeasible.
Agent 48 (Bayesian Adaptive): Enables Bayesian borrowing of information across basket cohorts to strengthen statistical power in small sub-groups.
Integrating digital biomarkers and real-world patient data
Integrate wearable device data, smartphone assessments, and ePRO for real-time efficacy and safety signals.
Deep-mine PROs to identify QoL signals that predict clinical benefit and payer acceptance.
Detects subtle improvements in gait, balance, and activity levels in CNS tumor patients that precede radiographic response by 4-6 weeks - enabling earlier efficacy assessment.
Agent 61 (HTA Submission Strategist): PRO and digital biomarker data feeds directly into HTA dossiers — NICE and G-BA increasingly require patient-reported and digital evidence for reimbursement.
Agent 52 (Data Quality Monitor): Validates wearable data quality, detecting sensor artifacts, missing data periods, and non-wear compliance issues.
Agent 59 (Cost-Effectiveness): Incorporates PRO-derived utility values (EQ-5D, SF-36) into QALY calculations for payer submissions.
Pfizer-level biostatistics: SAP generation, Bayesian adaptive design, interim analysis, and missing data methodology
Auto-generates ICH E9-compliant Statistical Analysis Plans with analysis population definitions (ITT/PP/mITT), primary/secondary endpoint methods, multiplicity adjustments, and SAS/R programming specifications.
Handles missing data per ICH E9(R1) estimand framework using MICE, PMM, tipping point analysis, and pattern-mixture models. Critical for FDA submission integrity.
Bayesian interim analysis, adaptive randomization, predictive probability of success, and posterior calculations. Essential for FORTE dose-escalation decisions.
DSMB-grade interim analysis with O'Brien-Fleming boundaries, conditional power under current trend, and sample size re-estimation capabilities.
FORTE's basket design across 4 sub-protocols creates unique statistical challenges: the Bayesian Adaptive Agent enables information borrowing across cohorts, while the SAP Generator ensures each sub-protocol has rigorous, pre-specified analysis plans that satisfy FDA expectations for tissue-agnostic submissions.
FDA-mandated data standards: SDTM/ADaM mapping, MedDRA coding, and continuous data quality monitoring
Automated SDTM domain mapping from raw CRF data, ADaM dataset generation, define.xml creation, and Pinnacle 21 validation rule checking for eCTD-ready submission packages.
Auto-codes AE verbatim terms to MedDRA preferred terms, runs SMQ-based safety signal grouping, handles multi-lingual normalization, and WHO Drug Dictionary coding for concomitant medications.
Automated cross-field validation, temporal logic checks, central monitoring signal detection, risk-based data review, and GCP compliance verification for data lock readiness.
CDISC compliance has been FDA-mandated since December 2016. Non-compliant submissions face Refuse-to-File decisions. This agent suite mirrors the Pfizer/Saama AI partnership that specifically targets CDISC automation — reducing data management costs by 40-60% while eliminating submission rejection risk.
Pharmacometrician-level analysis: population PK, exposure-response, and dose selection across sub-protocols
NONMEM-style compartmental modeling with covariate screening (SCM, COSSAC), visual predictive checks, and individual PK parameter estimation. Critical for PLX-120-03 dose selection across FORTE cohorts.
Models exposure-efficacy and exposure-safety relationships using logistic, Cox PH, and EMAX models. Quantifies probability of response by exposure quartile and safety margin.
MCP-Mod dose-response analysis, optimal dose selection, pediatric allometric scaling, and PBPK-informed drug-drug interaction predictions.
PLX-120-03 requires different dosing consideration for CNS tumors (Sub-Protocol A) vs solid tumors (Sub-Protocol B) due to BBB penetration dynamics. The PK/PD suite integrates with Agent 30 (BBB Dynamics) to optimize CNS-specific dosing while Agent 54 validates the therapeutic window across both populations — directly supporting FDA dose justification in the NDA.
ICH E3-compliant CSR generation, FDA/EMA response drafting, and label development
Automated ICH E3-compliant Clinical Study Report drafting — generates CONSORT flow diagrams, disposition tables, AE summary tables, efficacy endpoint tables, and patient safety narratives from agent outputs.
Drafts FDA/EMA information request responses, AdComm briefing document support, and Type A/B/C meeting preparation with regulatory precedent citation and quantitative B-R arguments.
Drafts USPI/SmPC with indication wording, safety language optimization, boxed warning assessment, and competitor label benchmarking in PLR format.
Traditional CSR drafting takes 3-6 months with a team of medical writers. This agent suite generates draft CSR sections in hours, cutting regulatory document preparation time by 70%+ and enabling faster NDA submission. Agent 57 reduces FDA response turnaround from weeks to days — critical during the review cycle where delays directly impact approval timelines.
Payer-ready evidence: cost-effectiveness, budget impact, and HTA submission strategies
QALY calculations, ICER modeling, Markov state-transition models, probabilistic sensitivity analysis, and cost-effectiveness acceptability curves across payer perspectives.
Budget impact analysis for payers/health systems with market share projections, displacement analysis, total cost of care modeling, and AMCP dossier generation.
Maps requirements for NICE, PBAC, CADTH, and G-BA. Prepares value dossiers, network meta-analyses for indirect comparisons, and reimbursement landscape mapping.
Oncology drugs face increasing payer scrutiny globally. PLX-120-03's tissue-agnostic positioning (basket trial) requires robust health economic evidence across multiple tumor types. Agent 72 (Comparative Effectiveness) feeds directly into ICER calculations, while Agent 45 (PRO Mining) provides utility data for QALY estimates — building the payer evidence package during the trial rather than after it.
Pfizer/Lokavant-level AI: site selection, patient recruitment, and enrollment velocity prediction
Multi-factor site scoring using historical performance, BRAF V600 patient density, competitor trial activity, PI publication record, and activation timeline prediction.
EHR-based patient matching, digital recruitment strategy, I/E criteria broadening simulation, diversity target planning, and screen failure rate prediction.
Real-time enrollment curve projection (Poisson/negative binomial), site-level performance tracking, country reallocation, and rescue scenario planning.
FORTE's rare tumor cohorts (Sub-Protocol C: ameloblastoma, craniopharyngioma) face extreme recruitment challenges with small global patient pools. This operations suite directly mirrors Pfizer's Lokavant AI feasibility partnership (2025) — treating site selection as continuous learning rather than a one-time decision, and enabling real-time enrollment rescue when sites underperform.
GCP auditing, protocol deviation analysis, and inspection readiness per ICH E6(R2)
Automated GCP compliance scoring per ICH E6(R2), SOP deviation detection, TMF artifact completeness tracking, and risk-based quality management (RBQM) signals.
Deviation classification (major/minor), impact-on-endpoint assessment, site-level trend analysis, and root cause identification with corrective action recommendations.
Mock inspection scenario simulation, high-risk site identification, document gap analysis, and inspector focus prediction based on historical FDA/EMA inspection patterns.
FDA GCP inspections can result in Warning Letters, clinical holds, or data exclusion. This suite provides continuous quality monitoring rather than point-in-time audits — identifying deviations in real-time and predicting which sites are most likely to trigger inspection findings. Critical for a multi-site, multi-country basket trial like FORTE.
Meta-cognitive agents: causal inference, contradiction resolution, and confidence calibration ensuring trustworthy AI outputs
Distinguishes true causal relationships from correlations using DAG construction, instrumental variable analysis, propensity score matching, mediation analysis, and causal forest estimation.
Identifies conflicting evidence across FORTE data streams, literature, and cross-trial comparisons. Reconciles multi-source evidence and manages competing hypotheses.
Quantifies uncertainty in ALL agent predictions with Bayesian credible intervals, model uncertainty quantification, ensemble aggregation, and overconfidence detection.
These IBC agents are the "quality control layer" that wraps all other agent outputs. The Confidence Calibration Agent ensures the CMO can trust AI predictions by providing calibrated uncertainty — distinguishing high-confidence findings (resistance predictions with >90% certainty) from exploratory signals (novel biomarker hypotheses with 40-60% confidence). Critical for clinical decision-making where overconfident AI could mislead treatment decisions.
External control arms, comparative effectiveness, companion diagnostics, and multi-omics integration
Post-marketing surveillance, EHR/claims data analysis, patient registry integration, synthetic control arm construction, and target trial emulation for regulatory-grade RWE.
Network meta-analysis with random effects, MAIC/STC for population-adjusted comparison, and standard-of-care benchmarking to position PLX-120-03 vs existing BRAF inhibitors.
CDx co-development strategy, BRAF V600 assay validation, biomarker qualification pathway planning, and clinical utility evidence generation for regulatory approval.
Integrates genomics, transcriptomics, proteomics, and metabolomics for comprehensive patient profiling and integrated biomarker panel discovery.
Mines failed BRAF inhibitor trials and negative studies to extract dose/schedule/population lessons and generate combination rescue hypotheses.
For FORTE's rare tumor cohorts (Sub-Protocol C), randomized control arms are infeasible. Agent 71 constructs regulatory-grade external control arms using real-world data. Agent 72 enables indirect comparison of PLX-120-03 vs vemurafenib/dabrafenib/encorafenib for label differentiation — critical for commercial positioning. Agent 73 ensures the BRAF V600 companion diagnostic strategy is optimized across tumor types.
25 Core + 20 Novel Insight + 30 Pharma-Grade Agents (based on Pfizer/Roche-level clinical trial methodologies)
Click any category below to expand and view individual agents, responsibilities, and capabilities.
How agents connect to uncover insights no single analysis could find alone
| Discovery Pathway | Primary Agents | Supporting Agents | Hidden Insight |
|---|---|---|---|
| Early Resistance Warning | 26, 27, 33 | 38, 18, 68 | Predict resistance 3-6 months before progression (causal validation via agent 68) |
| Super-Responder Identification | 35, 28 | 39, 27, 74 | Identify "cure signature" patients (multi-omic profiling via agent 74) |
| CNS-Specific Optimization | 29, 30, 31 | 44, 45, 53 | Pseudoprogression discrimination + CNS PK/PD optimization |
| Cross-Cohort Learning | 41, 42, 43 | 34, 16, 69 | Tissue-agnostic approval support (contradiction resolution across cohorts) |
| Safety Differentiation | 32, 10 | 33, 18, 70 | Validate paradox-breaker design with calibrated confidence |
| Salvage Opportunity | 36, 37 | 38, 33, 75 | Rescue near-miss responders (learn from prior BRAF trial failures) |
| Regulatory Acceleration NEW | 50, 56, 57 | 46, 47, 58 | CDISC-compliant datasets + auto-generated CSR + label draft = months faster NDA |
| Dose Precision NEW | 53, 54, 55 | 30, 48 | Population PK-driven dose optimization across CNS vs solid tumor sub-protocols |
| Market Access Strategy NEW | 59, 60, 61 | 72, 45 | Payer-ready evidence package: cost-effectiveness + budget impact + HTA positioning |
| Enrollment Rescue NEW | 62, 63, 64 | 41, 43 | AI-optimized site selection + recruitment for rare BRAF-altered tumor cohorts |